TickerTalks
Browse all tickers →
TickerTalks›$PHVS
PHPHVS

Pharvaris N.V.

$PHVS·$2.7B·Biotechnology·Healthcare
$37.55-1.3%YTD+34.3%1Y+57.7%
Price updated 7m ago·X counts updated 3d ago
PHPHVS
$PHVSPharvaris N.V.
$37.55-1.34%211 posts0.4×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PHVS on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

211X posts · last 7 days
Sep 3Sep 14
Chatter Meter
0.4×
QuietNormal · 1×Loud

How loud $PHVS's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's quieter than usual.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-16

Pharvaris posters read the fresh CHAPTER-3 deucrictibant data as strong: well-tolerated with no treatment-related serious adverse events (the Grade 3 and 4 events explicitly deemed unrelated to drug). Morgan Stanley sees a "superior injectable-like" profile and is hosting a KOL call Sep 10 to discuss the commercial opportunity. Type-3 HAE data (one patient attack-free, another 90% reduction) adds optionality, and hedge-fund ownership is meaningful. Muted price action is being pinned on a likely post-data raise, not thesis.

Read what X is saying about $PHVS

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PHVS — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-09-17

The move is getting stronger, with heavier trading behind it.

HAE biotech with clean Phase 3 data and a PDUFA-shaped year — the tape is holding up despite fresh insider selling.

Pharvaris is a late-stage biotech developing deucrictibant, an oral bradykinin-B2 receptor antagonist for hereditary angioedema (HAE) — a rare disease with a small but well-defined patient population and existing injectable competitors. Shares are up 34% YTD and 58% year-on-year on the fresh Phase 3 dataset.

  • The clinical setup is genuinely strong: CHAPTER-3 deucrictibant data showed the drug well-tolerated with no treatment-related serious adverse events (the Grade 3-4 events explicitly deemed unrelated), plus Type-3 HAE optionality with one patient attack-free and another 90% reduction — Morgan Stanley calls it a 'superior injectable-like' oral profile.
  • The tempering signal is insider-shaped: executive Wim Souverijns's Sept 15-16 sales of ~$1.7M (via M-Exempt + S-Sale sequence) plus Berndt Modig's smaller sale is real post-data monetization — normal but coordinated enough that the tape needs the next catalyst, not just the current dataset.

Nov 11 Q3 earnings, any PDUFA-related update, and the KOL call Morgan Stanley hosted are the switches — a specific FDA filing acceptance date breaks the coil upward, while another post-data capital raise or a competitive HAE readout with cleaner tolerability is what would seal a cooling.

Agrees with X sentimentLine up with the constructive X read — the CHAPTER-3 tolerability profile plus Type-3 HAE optionality plus 'muted price action likely priced for a raise' framing all match the filings. What the crowd is right about: hedge-fund ownership is meaningful and the fundamentals justify the setup regardless of the small insider cluster.

What to watch: Nov 11 Q3 earnings for cash runway, any PDUFA filing acceptance date, and the KOL call read-through. A specific FDA date breaks the coil upward; a fresh capital raise or a competitive HAE readout seals the cooling.

On the calendar: 2026-11-11 — Q3 2026 earnings

Read the AI verdict on $PHVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Developing oral and on-demand PDE2-inhibitor treatments for hereditary angioedema, a rare bradykinin-driven swelling disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PHVS.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $PHVS

Partial — late-stage biopharma developing disease therapies benefits from the biotech re-rating's multiple expansion; specific pipeline focus and Phase 3 data timing are the company-specific catalysts.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.3%YTD
+43.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-12.0How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-60.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-6.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.81$-0.75-8.5%
Q1 2026May 12, 2026$-0.70$-0.82+14.8%
Q1 2026Apr 2, 2026$-0.85$-0.71-18.3%
Q3 2025Nov 12, 2025$-0.70$-0.78+10.3%
Next earningsWed, Nov 11·consensus EPS $-0.82

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.70$-37.8M
Q1 FY26$0———$-0.61$-49.6M
Q4 FY25$0———$-0.79$-38.0M
Q3 FY25$0———$-0.60$-30.7M

Forward consensus

5-year forecast · up to 12 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.3M$764K – $1.9M-$2.83-$3.09 – -$2.179
FY27$32.2M$3.2M – $54.4M-$2.74-$3.53 – -$1.9212
FY28$166.7M$123.2M – $211.7M-$0.89-$3.31 – -$0.1510
FY29$0$0 – $0$1.73$0.76 – $2.590
FY30$0$0 – $0$5.03$2.22 – $7.520

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.75%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+25.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 33.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.5% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-2.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 15Wim SouverijnsChief Commercial Officer6.1K sh$237KSellSep 14Wim SouverijnsChief Commercial Officer20.0K sh$786KSellSep 14Berndt ModigCEO2.3K sh$90KSellSep 11Peng LuPresident15.0K sh$602KSellSep 10Anne LesageChief Early Development30.0K sh$1.1MSellSep 9Robert GlassmanDirector8.0K sh$300KSellSep 8Peng LuPresident15.0K sh$610KSellAug 14Berndt ModigCEO2.3K sh$80KSellJul 13Berndt ModigCEO2.3K sh$80KSellJun 30Anne LesageChief Early Development58.6K sh$2.1M
1–10 of 21
+ 20 other (12 exempts · 8 inkinds) in window

See when $PHVS insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)May 8424B5
3/ANew insider — initial holdingsApr 33/A
+ 12 other (8 6-Ks · 3 13Gs · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stockdefenseworld.net·1d agoPharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLCdefenseworld.net·1d agoPharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com·2d agoPHVS Stock Rises 10% in a Month: What Is Driving the Rally?zacks.com·2d agoPharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Winseekingalpha.com·8d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $PHVS on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport